NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球呼吸道感染診斷市場:2020-2027

Global Respiratory Infectious Disease Diagnostics Market - 2020-2027

出版商 DataM Intelligence 商品編碼 961521
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
全球呼吸道感染診斷市場:2020-2027 Global Respiratory Infectious Disease Diagnostics Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介

呼吸系統疾病日益嚴重的負擔和產品的技術進步正在推動市場。由於人口老齡化和人們生活方式的改變,預計未來幾年呼吸系統疾病將會增加。因此,早期診斷和治療非常重要,有望促進市場增長。

由於最近的大流行而在全球傳播的COVID-19感染也是在預測期內推動診斷需求的主要因素。根據當前的統計數據,到2020年4月,全球有608萬人感染了COVID-19,這可能會影響對迅速診斷測試的需求。該因素可能會在預測期內推動呼吸道感染診斷市場。

本報告調查了全球呼吸道感染診斷市場,並提供了系統的信息,例如市場概況,按細分市場和地區劃分的市場規模預測,主要公司的概況以及競爭條件的分析。

目錄

第1章全球呼吸道感染診斷市場:調查方法/範圍

  • 調查方法
  • 調查目的/範圍

第2章全球呼吸道感染診斷市場:市場定義/概述

第3章全球呼吸道感染診斷市場:執行摘要

  • 市場細分:按疾病類型
  • 市場細分:按檢驗類型
  • 市場細分:按最終用戶
  • 市場細分:按地區

第4章全球呼吸道感染診斷市場:市場動態

  • 市場影響因素
    • 促進因素
    • 抑製器
  • 影響分析
  • 市場機會

第5章全球呼吸道感染診斷市場:行業因素

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析
  • 價格分析
  • 產品分析
  • 售後服務分析

第6章全球呼吸道感染診斷市場:按疾病類型劃分

  • 簡介
  • 市場規模分析/同比增長率分析:按疾病類型
  • 市場吸引力指數:按疾病類型劃分
    • 冠狀病毒感染
    • 中東呼吸綜合症(MERS)
    • 肺結核
    • 其他

第7章全球呼吸道感染診斷市場:按測試類型

  • 簡介
  • 市場規模分析/同比增長率分析:按檢驗類型
  • 市場吸引力指數:按檢驗類型
    • 圖像檢查
    • 機械檢查
    • 體外診斷測試
    • 其他

第8章全球呼吸道感染診斷市場:按最終用戶分類

  • 簡介
  • 市場規模分析/同比增長率分析:按最終用戶劃分
  • 市場吸引力指數:按應用
    • 醫院
    • 診斷中心
    • 其他

第9章呼吸道感染診斷市場:按地區

  • 簡介
  • 市場規模分析/同比增長率分析:按地區
  • 市場吸引力指數:按地區
  • 北美
    • 簡介
    • 特定地區的主要動態
    • 市場規模分析/同比增長率分析:按疾病類型
    • 市場規模分析/同比增長率分析:按測試類型
    • 市場規模分析/同比增長率分析:按最終用戶劃分
    • 市場規模分析/同比增長率分析:按國家
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第10章競爭情況

  • 競爭情景
  • 市場定位/份額分析
  • 併購分析

第11章公司簡介

  • 雅培實驗室
    • 公司簡介
    • 投資組合/說明
    • 主要亮點
    • 財務概覽
  • Becton Dickinson & Company
  • Thermo Fisher Scientific Inc.
  • Alere, Inc.
  • Koninklijke Philips N.V.
  • Cardinal Health
  • COSMED
  • Smiths Group plc
  • NIHON KOHDEN CORPORATION
  • F. Hoffmann-La Roche AG.

第12章全球呼吸道感染診斷市場:重要考慮因素

第13章全球呼吸道感染診斷Market-DataM

  • 附錄
  • 關於我們的公司和服務
  • 聯繫我們
目錄

Market Overview

Respiratory infections are caused by virus, bacteria, and other microbes, which further infect the respiratory system including the lungs, throat, and airways. Spread of infections is often through mucus and saliva that is usually expelled when the person sneezes, coughs, or laughs. Few of the germs are also spread though droplets that spread through air and also spread through travelling, which causes respiratory infections. Furthermore, some people can be infected by touching the remaining microbes on the surface, or touching contaminated hands.

Rising levels of hazardous gases and pollutants will lead to various lung disorders such as respiratory diseases including bronchitis, asthma, COPD, and Emphysema, among others. Further, a growing population base in developed and underdeveloped countries and the rising inclination towards a sedentary lifestyle may contribute to the market growth. COVID-19 outbreak has affected patients with severe respiratory distress, thereby increasing the demand for respiratory disease testing market.

Various conditions affect different parts of respiratory system and hinder the ability to breathe. These conditions can be chronic or infectious. Chronic lung diseases fall into one of two main classes, obstructive or restrictive. People with weakened lungs and immune systems are more vulnerable to infectious respiratory conditions. Some individuals have multiple lung conditions.

Market Dynamics:

The market is driven is the rising burden of respiratory diseases and technological advancements in the products. Chronic Obstructive Pulmonary Disease is a progressive lung disorder which causes reduction in airflow. According to the World Health Organization, 90% of the COPD deaths occur in low- and middle-income countries. Approximately 251 million cases of COPD were reported globally as per the study of the Global Burden of Disease Study. It is expected to increase in the coming years due to increasing aging population and changing lifestyle of people. Therefore, early diagnosis and treatment is very important which is expected to boost the market growth.

Recent pandemic resulting into widespread COVID 19 infections across the globe is a major factor that is estimated to boost the demand for diagnosis during forecast period. As per current statistics, in April 2020, 6.08 million people across globe were infected with COVID 19 diseases, and this is likely to impact the need for rapid diagnostics testing. This factor is likely to boost the respiratory infectious diagnostics market during forecast period.

According to data published in January 2020, 2519 laboratory-conformed cases of Middle East respiratory syndrome (MERS), were reported, which includes 866 associated deaths globally. Majority of cases reported were from Saudi Arabia (2121 cases), including 788 related deaths with a higher fatality rate of 37.1%. Moreover, the emergence of COVID-19 pandemic has driven the demand for faster diagnosis. According to statistics, in May 2020, there were around 6.08 million COVID-19 cases reported globally, which boosts the need for early diagnosis of diseases. This factor will drive the growth of market in the forecast period.

Rapid rise in burden of chronic obstructive pulmonary disorders such as chronic bronchitis, emphysema, asthma, and other lung diseases such as tuberculosis, pneumonia, is estimated to boost the respiratory infectious disease diagnostics market. Furthermore, rising lower respiratory infectious disease drives the need for early detection, which further drivers the demand for diagnostics tests. This factor will drive the growth of market in the forecast period.

However, stringent regulatory framework coupled with unfavorable reimbursement policies and low awareness rate among the patient population will hamper the growth of the market in the forecast period.

Segment Analysis

The global respiratory infectious disease diagnostics market is segmented based on disease type by coronavirus infections, Middle East Respiratory Syndrome (MERS), tuberculosis, others . The coronavirus infections segment held the largest market share. According to the WHO, SARS-CoV-2 has spread to over 150 countries with over 460,000 confirmed cases and over 20,000 deaths as of 27th March 2020. According to an article published in the World Economic Forum in March 2020, among the 500 people being hospitalized in the U.S., 20% were aged between 20 to 44 years and 18 % were aged between 45-54 years. This factor would drive the growth of the market in the forecast period.

People with existing illnesses such as cardiovascular disease, chronic respiratory disease, hypertension, and diabetes are expected to experience a higher than average fatality rate. Moreover, according to the Chinese CDC, males are more vulnerable to becoming severely ill with the virus than women. The male fatality rate is 2.8% and the female fatality rate is 1.7%. This factor will drive the growth of market in the forecast period.

The tuberculosis segment is expected to have positive market growth in the forecast period. Tuberculosis is a bacterial infection that affects the lungs and other parts of the body. TB can be inactive, or latent, for many years. The landscape of TB diagnostics has changed dramatically during the past ten years. Moreover, in response to WHO's Global TB Program, it has implemented a systematic and dynamic process, that is used to evaluate technologies and develop policies.

The high-risk countries are undertaking national efforts to reduce disease burden. For instance, the Chinese government obtained financial aid through a partnership with the Bill & Melinda Gates Foundation to enhance detection and treatment of TB. The foundation supported the initiative through a grant of USD 33 million for five years from 2009-2014. This factor will drive the growth of the market in the forecast period.

Further, the market is also classified based on test type as imaging tests, mechanical tests, in-vitro diagnostic tests and others. The imaging tests segment is held the largest market share. The prime reason for the dominance of the segment is increased adoption of x-ray imaging and other imaging modalities for better visualization and a clear picture of disease condition.

An imaging test is a way to let doctors see what's going on inside patient's body. These tests send forms of energy (like x-rays, sound waves, radioactive particles, or magnetic fields) through the body. The body tissues change the energy patterns to make an image or picture. These pictures show how patient's insides look and work so that health care providers can see changes that may be caused by diseases like lungs cancer.

Many health care providers plan x-rays or other imaging tests before treatment starts. These pictures are then used to track changes during treatment. These are called baseline studies because they show how things looked at the start. They can be compared with later images to see the results of treatment over time. This factor will drive the growth of market in the forecast period.

In-vitro diagnostics tests has positive growth in the Respiratory Disease Testing market. The major contributing factor for the market growth is the shift from traditional diagnostics to a new generation diagnostics that work at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, and polymerase chain reaction (PCR) and next-generation sequencing (NGS). Recently (2020), Qiagen received a CE mark in the Europe for QIAstat-Dx test kit for the detetction of SARS-CoV-2 coronavirus.

Geographical Presentation

By region, the global respiratory infectious disease diagnostics market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global respiratory infectious disease diagnostics market and is expected to grow at the highest CAGR during the forecast period due to growing burden of respiratory diseases and higher prevalence of smoking.

According to the Centre for Disease Control and Prevention, in 2018, the prevalence of Asthma was found to be around 6.2% in male and 9.1% in female in the United States. Furthermore, around 6.2% of people were reported with chronic obstructive pulmonary diseases in the United States. Hence, these factors are expected to drive the growth of market in the forecast period.

Adoption of rapid diagnostics tests for faster diagnosis of respiratory infectious diseases is another key factor that is anticipated to augment the respiratory infectious disease diagnostics market in the region. As per CDC statistics, in May 2020, the Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel is efficient in detecting the SARS-CoV-2 virus in respiratory specimens. The USFDA also offered its Emergency Use Authorization (EUA) for this test in February 2020. These factors are expected to drive the growth of market in the forecast period.

The Europe was the second-largest market followed by Asia Pacific, owing to the rising prevalence of COPD disease in the region. For instance, according to the European Respiratory Nurses Association (ERNA), 259,000 people die of COPD each year in the EU. Moreover, rising cases of COVID 19 in Italy, Spain, the U.K. and other countries across Europe is boosting the need for diagnosis of respiratory infectious diseases across the region.

In Feb 2020, with respect to rising COVID diseases, the molecular diagnostics tests, serology tests, and antigen tests have been approved for faster diagnosis of the COVID 19 disease. Hence, these factors are expected to drive the growth of market in the region.

Competitive Analysis

The global respiratory infectious disease diagnostics market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Abbott Laboratories, Thermo Fisher Scientific Inc., Alere, Inc., Koninklijke Philips N.V., Cardinal Health, COSMED, Smiths Group plc, NIHON KOHDEN CORPORATION, Becton, Dickinson and Company, and F. Hoffmann-La Roche AG. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the respiratory infectious disease diagnostics across the globe. For instance, in August 2020, Novacyt an international specialist in clinical diagnostics, announces the launch of its CE-Mark approved polymerase chain reaction (PCR) respiratory test panel, Winterplex™. The test panel is designed to be used on any open PCR platform, including the Company's rapid, portable q32 instrument.

Why Purchase the Report?

  • Visualize the composition of the global respiratory infectious disease diagnostics market products in terms of disease type, test type and end user and highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the global respiratory infectious disease diagnostics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global respiratory infectious disease diagnostics market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • *The global respiratory infectious disease diagnostics market report will provide access to approximately 62 market data tables, 54 figures, and 200 pages

Target Audience2022

  • Industry Investors/Investment Bankers
  • Suppliers/Buyers
  • Education & Research Institutes
  • Manufacturers
  • Research Professionals
  • Emerging Companies
  • Distributors

Table of Contents

1. Global Respiratory Infectious Disease Diagnostics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Respiratory Infectious Disease Diagnostics Market - Market Definition and Overview

3. Global Respiratory Infectious Disease Diagnostics Market - Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Test Type
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Global Respiratory Infectious Disease Diagnostics Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Burden of Respiratory Diseases
      • 4.1.1.2. Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Framework
  • 4.2. Impact Analysis
  • 4.3. Opportunity

5. Global Respiratory Infectious Disease Diagnostics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Product Analysis
  • 5.6. Post Sales Services Analysis

6. Global Respiratory Infectious Disease Diagnostics Market - By Disease Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.3. Market Attractiveness Index, By Disease Type
    • 6.3.1. Coronavirus Infections *
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
    • 6.3.2. Middle East Respiratory Syndrome (MERS)
    • 6.3.3. Tuberculosis
    • 6.3.4. Others

7. Global Respiratory Infectious Disease Diagnostics Market - By Test Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 7.3. Market Attractiveness Index, By Test Type
    • 7.3.1. Imaging Tests
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
    • 7.3.2. Mechanical Tests
    • 7.3.3. In-vitro Diagnostic Tests
    • 7.3.4. Others

8. Global Respiratory Infectious Disease Diagnostics Market - By End-User

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 8.3. Market Attractiveness Index, By Application
    • 8.3.1. Hospitals
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
    • 8.3.2. Diagnostic Centers
    • 8.3.3. Others

9. Global Respiratory Infectious Disease Diagnostics Market - By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. U.S.
      • 9.4.6.2. Canada
      • 9.4.6.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.6.1. Brazil
      • 9.6.6.2. Argentina
      • 9.6.6.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.6.1. China
      • 9.7.6.2. India
      • 9.7.6.3. Japan
      • 9.7.6.4. Australia
      • 9.7.6.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Global Respiratory Infectious Disease Diagnostics Market Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Respiratory Infectious Disease Diagnostics Market Company Profiles

  • 11.1. Abbott Laboratories *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Developments
    • 11.1.4. Financial Overview
  • 11.2. Becton Dickinson & Company
  • 11.3. Thermo Fisher Scientific Inc.
  • 11.4. Alere, Inc.
  • 11.5. Koninklijke Philips N.V.
  • 11.6. Cardinal Health
  • 11.7. COSMED
  • 11.8. Smiths Group plc
  • 11.9. NIHON KOHDEN CORPORATION
  • 11.10. F. Hoffmann-La Roche AG.
  • List is not exhaustive

12. Global Respiratory Infectious Disease Diagnostics Market - Premium Insights

13. Global Respiratory Infectious Disease Diagnostics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us